LiGHT 2026

Charles River Laboratories Acquires KWS BioTest

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

WebMD Ignite Ruby Transforms Healthcare Marketing...

WebMD Ignite has announced the launch of WebMD Ignite...

Mayo Clinic Study Validates AI Tool...

Researchers at Mayo Clinic have found that an artificial...

MHRA Outlines New Agenda for AI...

The United Kingdom’s Medicines and Healthcare products Regulatory Agency...

Charles River Laboratories International, Inc. announced that it has acquired KWS BioTest, a leading contract research organization (CRO) specializing in in vitro and in vivo discovery testing services for immuno-oncology and inflammatory and infectious diseases.

The addition of KWS enhances Charles River’s discovery expertise, with complementary offerings that provide our clients with additional tools in the active therapeutic research areas of oncology and immunology.

James C. Foster, Chairman, President and Chief Executive Officer of Charles River, said, “The addition of KWS strategically expands Charles River’s existing discovery capabilities in the field of immunology, which is critical given the importance of new therapies which harness the human immune system. In addition to enhancing our position as the premier single-source provider for a broad portfolio of discovery services, KWS increases our ability to support clients’ early-stage drug research in critical therapeutic areas, and expands our geographic footprint in the United Kingdom.”

The purchase price was approximately £15 million in cash (approximately $20 million based on current exchange rates), subject to certain post-closing adjustments. In addition to the initial purchase price, the transaction includes a potential additional payment of up to £3 million based on future performance (approximately $4 million based on current exchange rates). The transaction is not expected to be material to 2018 GAAP or non-GAAP results from operations.

About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com

Charles River Laboratories International, Inc.
Investor Contact:
Susan E. Hardy, 781-222-6190
Corporate Vice President, Investor Relations
susan.hardy@crl.com
or
Media Contact:
Amy Cianciaruso, 781-222-6168
Corporate Vice President, Public Relations
amy.cianciaruso@crl.com

Hospital & Healthcare Management brings together the global healthcare industry — from hospital administrators and clinical directors to health technology innovators and policy leaders — through trusted editorial, market intelligence, and digital engagement.

Our 2026 Media Pack offers integrated solutions to reach your audience:

  • Magazine & Digital Editions Showcase your brand within premium healthcare industry coverage read by executives and decision - makers worldwide.
  • Industry Insights & Reports Align with data - driven analysis, trend reports, and regional roundups across the global hospital and healthcare management value chain.
  • Brand Authority & Credibility Position your company as a thought leader through expert commentary, interviews, and special features.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

– Leave Message for Us to Get Back

Latest stories

Related stories

Mayo Clinic Study Validates AI Tool DEXI for Skin Lesion Assessment

Researchers at Mayo Clinic have found that an artificial...

MHRA Outlines New Agenda for AI Medical Devices at AdvaMed

The United Kingdom’s Medicines and Healthcare products Regulatory Agency...

UK Confirms Indefinite Use of CE Marked Medical Devices

The United Kingdom government has officially confirmed the indefinite...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »